B cells produce less IL-10, IL-6 and TNF-α in myasthenia gravis

References

• Vincent, A., J. Palace, and D. Hilton-Jones. 2001. Myasthenia gravis. Lancet. 357: 2122–2128
   PubMed Web of Science ®Google Scholar
• Drachman, D. B. 1994. Myasthenia gravis. N. Engl. J. Med. 330: 1797–1810
   PubMed Web of Science ®Google Scholar
• Vincent, A., J. McConville, M. E. Farrugia, et al. 2003. Antibodies in myasthenia gravis and related disorders. Ann. N. Y. Acad. Sci. 998: 324–335
   PubMed Web of Science ®Google Scholar
• Rodgaard, A., F. C. Nielsen, R. Djurup, et al. 1987. Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3. Clin. Exp. Immunol. 67: 82–88
   PubMed Web of Science ®Google Scholar
• McConville, J., M. E. Farrugia, D. Beeson, et al. 2004. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann. Neurol. 55: 580–584
   PubMed Web of Science ®Google Scholar
• Leite, M. I., S. Jacob, S. Viegas, et al. 2008. IgG1 antibodies to acetylcholine receptors in ‘seronegative' myasthenia gravis. Brain 131: 1940–1952
   PubMed Web of Science ®Google Scholar
• Pevzner, A., B. Schoser, K. Peters, et al. 2012. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J. Neurol. 259: 427–435
   PubMed Web of Science ®Google Scholar
• Zhang, B., J. S. Tzartos, M. Belimezi, et al. 2012. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch. Neurol. 69: 445–451
   PubMed Web of Science ®Google Scholar
• Zhang, B., C. Shen, B. Bealmear, et al. 2014. Autoantibodies to agrin in myasthenia gravis patients. PLoS One 9: e91816
   PubMed Web of Science ®Google Scholar
• Milani, M., N. Ostlie, H. Wu, et al. 2006. CD4+ T and B cells cooperate in the immunoregulation of experimental autoimmune myasthenia gravis. J. Neuroimmunol. 179: 152–162
   PubMed Web of Science ®Google Scholar
• Yi, Q., R. Ahlberg, R. Pirskanen, and A. K. Lefvert. 1994. Acetylcholine receptor-reactive T cells in myasthenia gravis: evidence for the involvement of different subpopulations of T helper cells. J. Neuroimmunol. 50: 177–186
   Google Scholar
• Zhang, G. X., V. Navikas, and H. Link. 1997. Cytokines and the pathogenesis of myasthenia gravis. Muscle Nerve 20: 543–551
   PubMed Web of Science ®Google Scholar
• Tangye, S. G., A. Ferguson, D. T. Avery, et al. 2002. Isotype switching by human B cells is division-associated and regulated by cytokines. J. Immunol. 169: 4298–4306
   Google Scholar
• Huang, W.-X., P. Huang, S. Fredrikson, et al. 2000. Decreased mRNA expression of TNFa and IL-10 in non-stimulated peripheral blood mononuclear cells in myasthenia gravis. Eur. J. Neurol. 7: 195–202
   Google Scholar
• Link, J., V. Navikas, M. Yu, et al. 1994. Augmented interferon-gamma, interleukin-4 and transforming growth factor beta mRNA expression in blood mononuclear cells in myasthenia gravis. J. Neuroimmunol. 51: 185–192
   Google Scholar
• Yoshikawa, H., K. Satoh, Y. Yasukawa, and M. Yamada. 2002. Cytokine secretion by peripheral blood mononuclear cells in myasthenia gravis. J. Clin. Neurosci. 9: 133–136
   Google Scholar
• Huang, Y. M., P. Kivisakk, V. Ozenci, et al. 1999. Increased levels of circulating acetylcholine receptor (AChR)-reactive IL-10-secreting cells are characteristic for myasthenia gravis (MG). Clin. Exp. Immunol. 118: 304–308
   Google Scholar
• Duddy, M. E., A. Alter, and A. Bar-Or. 2004. Distinct profiles of human B cell effector cytokines: a role in immune regulation? J. Immunol. 172: 3422–3427
   PubMed Web of Science ®Google Scholar
• Pistoia, V. 1997. Production of cytokines by human B cells in health and disease. Immunol. Today 18: 343–350
   PubMedGoogle Scholar
• Luu, V. P., M. I. Vazquez, and A. Zlotnik. 2014. B cells participate in tolerance and autoimmunity through cytokine production. Autoimmunity 47: 1–12
   PubMed Web of Science ®Google Scholar
• Burdin, N., C. Van Kooten, L. Galibert, et al. 1995. Endogenous IL-6 and IL-10 contribute to the differentiation of CD40-activated human B lymphocytes. J. Immunol. 154: 2533–2544
   PubMed Web of Science ®Google Scholar
• Agematsu, K., H. Nagumo, F. C. Yang, et al. 1997. B cell subpopulations separated by CD27 and crucial collaboration of CD27+ B cells and helper T cells in immunoglobulin production. Eur. J. Immunol 27: 2073–2079
   PubMed Web of Science ®Google Scholar
• Duddy, M., M. Niino, F. Adatia, et al. 2007. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J. Immunol. 178: 6092–6099
   PubMed Web of Science ®Google Scholar
• Jagannathan, M., M. McDonnell, Y. Liang, et al. 2010. Toll-like receptors regulate B cell cytokine production in patients with diabetes. Diabetologia 53: 1461–1471
   Google Scholar
• Fillatreau, S., C. H. Sweenie, M. J. McGeachy, et al. 2002. B cells regulate autoimmunity by provision of IL-10. Nat. Immunol. 3: 944–950
   PubMed Web of Science ®Google Scholar
• Nakano, S., S. Morimoto, J. Suzuki, et al. 2008. Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus. Rheumatology (Oxford) 47: 145–149
   PubMed Web of Science ®Google Scholar
• Pisetsky, D. S. 2008. The role of innate immunity in the induction of autoimmunity. Autoimmun. Rev. 8: 69–72
   PubMed Web of Science ®Google Scholar
• Baccam, M., and G. A. Bishop. 1999. Membrane-bound CD154, but not CD40-specific antibody, mediates NF-kappaB-independent IL-6 production in B cells. Eur. J. Immunol. 29: 3855–3866
   PubMedGoogle Scholar
• Kawanami, S., S. Mori, H. Kamei, et al. 1990. Cellular immunity in myasthenia gravis after thymectomy and corticosteroid therapy. Jpn. J. Med. 29: 138–145
   Google Scholar
• Kohler, S., T. O. Keil, M. Swierzy, et al. 2013. Disturbed B cell subpopulations and increased plasma cells in myasthenia gravis patients. J. Neuroimmunol. 264: 114–119
   Google Scholar
• Baumgarth, N. 2000. A two-phase model of B-cell activation. Immunol. Rev. 176: 171–180
   PubMed Web of Science ®Google Scholar
• Wheeler, K., J. D. Pound, J. Gordon, and R. Jefferis. 1993. Engagement of CD40 lowers the threshold for activation of resting B cells via antigen receptor. Eur. J. Immunol. 23: 1165–1168
   Google Scholar
• Harp, C. T., S. Ireland, L. S. Davis, et al. 2010. Memory B cells from a subset of treatment-naive relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-gamma production in response to myelin basic protein and myelin oligodendrocyte glycoprotein. Eur. J. Immunol. 40: 2942–2956
   PubMed Web of Science ®Google Scholar
• Sun, F., S. S. Ladha, L. Yang, et al. 2014. Interleukin-10 producing-B cells and their association with responsiveness to rituximab in myasthenia gravis. Muscle Nerve 49: 487–494
   PubMed Web of Science ®Google Scholar
• Barr, T. A., P. Shen, S. Brown, et al. 2012. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6 producing B cells. J. Exp. Med. 209: 1001–1010
   PubMed Web of Science ®Google Scholar
• Nielsen, C. H., L. Hegedüs, K. Rieneck, et al. 2007. Production of interleukin (IL)-5 and IL-10 accompanies T helper cell type 1 (Th1) cytokine responses to a major thyroid self-antigen, thyroglobulin, in health and autoimmune thyroid disease. Clin. Exp. Immunol. 147: 287–295
   PubMed Web of Science ®Google Scholar
• Link, H., O. Olsson, J. Sun, et al. 1991. Acetylcholine receptor-reactive T and B cells in myasthenia gravis and controls. J. Clin. Invest. 87: 2191–2196
   PubMed Web of Science ®Google Scholar
• Lampropoulou, V., K. Hoehlig, T. Roch, et al. 2008. TLR-activated B cells suppress T cell-mediated autoimmunity. J. Immunol. 180: 4763–4773
   PubMed Web of Science ®Google Scholar
• Ruprecht, C. R., and A. Lanzavecchia. 2006. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur. J. Immunol. 36: 810–816
   PubMed Web of Science ®Google Scholar
• Cufi, P., N. Dragin, J. M. Weiss, et al. 2013. Implication of double-stranded RNA signaling in the etiology of autoimmune myasthenia gravis. Ann. Neurol. 73: 281–293
   Google Scholar
• Fillatreau, S., D. Gray, and S. M. Anderton. 2008. Not always the bad guys: B cells as regulators of autoimmune pathology. Nat. Rev. Immunol. 8: 391–397
   PubMed Web of Science ®Google Scholar
• Stubgen, J. P. 2008. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders. J. Neuroimmunol. 204: 1–12
   Google Scholar
• Berrih-Aknin, S., S. Ragheb, R. Le Panse, and R. P. Lisak. 2013. Ectopic germinal centers, BAFF and anti-B-cell therapy in myasthenia gravis. Autoimmun. Rev. 12: 885–893
   PubMed Web of Science ®Google Scholar